Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension

Circulation

Volumn 111, Issue 23, 2005, Pages 3105-3111

  Sitbon, Olivier ^a   Humbert, Marc ^a   Jaïs, Xavier ^a   Ioos, Vincent ^a   Hamid, Abdul M ^a   Provencher, Steeve ^a   Garcia, Gilles ^a   Parent, Florence ^a   Hervé, Philippe ^a   Simonneau, Gérald ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Calcium channel blockers; Follow up studies; Hypertension, pulmonary; Nitric oxide; Pulmonary circulation

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; NIFEDIPINE; NITRIC OXIDE; PROSTACYCLIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEMODYNAMICS; HUMAN; IDIOPATHIC DISEASE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; CALCIUM CHANNEL BLOCKERS; DRUG EVALUATION; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITRIC OXIDE; PULMONARY ARTERY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 20544448927     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.488486     Document Type: Article

References (22)

1. Rubin LJ. Primary pulmonary hypertension. Chest. 1993;104:236-250.
2. Humbert M, Nunes H, Sitbon O, Parent F, Herve P, Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med. 2001;22:459-475.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1236.
4. Packer M. Vasodilator therapy for primary pulmonary hypertension. Ann Intern Med. 1985;103:258-270.
5. Rubin LJ. Calcium channel blockers in primary pulmonary hypertension. Chest. 1985;88:257S-260S.
6. Rich S, Brundage BH, Levy PS. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation. 1985;71:1191-1196.
7. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E, Fishman AP. Primary pulmonary hypertension: vascular structure, morphometry and responsiveness to vasodilators agents. Circulation. 1989;80:1207-1221.
8. Rich S, Kaufmann E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J Am Coll Cardiol. 1991;18:1323-1327.
9. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
10. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J. 1998;12:265-270.
11. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982;66:334-338.
12. Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol. 1992;19:1060-1064.
13. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:5S-12S.
14. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132:919-923.
15. Simonneau G, Hervé P, Petitpretz P, Girard P, Salmeron S, Escourrou P, Baudoin C, Nebout T, Duroux P. Detection of a reversible component in primary pulmonary hypertension: value of prostacyclin acute infusion. Am Rev Respir Dis. 1986;133:A223. Abstract.
16. Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Hervé P, Raffestin B, Simonneau G. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med. 1995;151:384-389.
17. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, Levy PC, Reid LM, Vreim CE, Williams GW. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107:216-223.
18. Raffy O, Azarian R, Brenot F, Parent F, Sitbon O, Petitpretz P, Hervé P, Duroux P, Dinh-Xuan AT, Simonneau G. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation. 1996;93:484-488.
19. Hoeper MM, Wilke T, Welte T, Breuer H-WM, Wagner TOF. How effective is the treatment with high-dose nifedipine for primary pulmonary hypertension? Semin Respir Crit Care Med. 1994;15:490-494.
20. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:40S-47S.
21. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, Niedermeyer J, Fabel H, Seeger W, for the German PPH Study Group. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol. 2000;35:176-182.
22. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Parent F, Hervé P, Simonneau G. Acute vasodilator responsiveness and long-term response to calcium-channel blockers in different forms of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:A210. Abstract.